LXE408 + AmBisome®
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Visceral Leishmaniasis
Conditions
Primary Visceral Leishmaniasis
Trial Timeline
Dec 27, 2022 → Dec 30, 2025
NCT ID
NCT05593666About LXE408 + AmBisome®
LXE408 + AmBisome® is a phase 2 stage product being developed by Novartis for Primary Visceral Leishmaniasis. The current trial status is active. This product is registered under clinical trial identifier NCT05593666. Target conditions include Primary Visceral Leishmaniasis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05593666 | Phase 2 | Active |
Competing Products
20 competing products in Primary Visceral Leishmaniasis